Clinical trials: Breast Density
Breast Cancer
Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid
The primary objective is, first, the comparison of tamoxifen and anastrozole and, second, the comparison of zoledronate added to standard adjuvant therapy with controls according to disease-free survival (DFS) in premenopausal…
- Trial name
- NCT00295646
- Testing
- tamoxifen, anastrozole, zoledronic acid
- Where
- 72 sites in Austria, Germany
- Volunteers
- 1,803 people
- Sponsor
- Austrian Breast & Colorectal Cancer Study Group
Breast Cancer
Improving Utilization of Supplemental Breast MRI Screening for Women With Extremely Dense Breasts
The goal of this study is to increase MRI utilization among women with extremely dense breasts. The main question it seeks to answer is whether nudging of the provider, patient, or both increases the uptake of MRI among this…
- Trial name
- NCT05787249
- Testing
- Patient nudge, Provider nudge
- Where
- United States
- Volunteers
- 1,358 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Breast Cancer, Mammographic Density
Karolinska Interventional Study of Mammograhic Density (Karisma-1)
A feasibility study, randomising to either 10 or 20 mg of tamoxifen. The primary aim is to identify the time to mammographic density change and piloting the procedures.
- Trial name
- Karisma-1 (NCT04079517)
- Testing
- Tamoxifen
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Karolinska Institutet
Breast Neoplasms
Exemestane and Celecoxib in Postmenopausal Women at High Risk for Breast Cancer
The primary goal of this 5-year study is to determine whether exemestane alone or in combination with celecoxib decreases breast tissue density in healthy postmenopausal women at high risk for breast cancer.
- Trial name
- NCT00073073
- Testing
- Exemestane, Calcium carbonate, Vitamin D
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- Georgetown University
Breast Cancer
Sulindac and Breast Density in Women at Risk of Developing Breast Cancer
The primary objective of this study is to determine if sulindac at a dose of 150 mg twice a day for 12 months reduces breast density in postmenopausal women at elevated risk of breast cancer when compared to a placebo control.
- Trial name
- NCT04542135
- Testing
- Sulindac Pill
- Where
- 2 sites in United States
- Volunteers
- 61 people
- Sponsor
- Alison Stopeck
Dense Breasts
RANKL Inhibition and Mammographic Breast Density
Data supporting a role for RANKL signaling in mammographic density and breast cancer development has begun to emerge, but clinical trial data providing definitive evidence that would allow the adoption of RANKL inhibition in…
- Trial name
- TRIDENT (NCT04067726)
- Testing
- Denosumab, Calcium, Vitamin D3
- Where
- United States
- Volunteers
- 210 people
- Sponsor
- Washington University School of Medicine
Osteoporosis, Postmenopausal
Safety/Efficacy of Letrozole Monotherapy or in Combination With Zoledronic Acid as Extended Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer
This was a prospective, randomized, open-label, two arm phase III trial designed to evaluate the efficacy and safety of zoledronic acid in preventing bone loss in postmenopausal women with operable breast cancer who had received…
- Trial name
- NCT00332709
- Testing
- Letrozole, Zoledronic acid
- Where
- 23 sites in Germany
- Volunteers
- 83 people
- Sponsor
- Novartis
Osteoporosis
Study Evaluating Changes In Mammographic Breast Density
The objective of the study is to evaluate quantitative changes in mammographic breast density from baseline to 24 months in postmenopausal women receiving daily doses of either BZA 20 mg/CE 0.45 mg, BZA 20 mg/CE 0.625 mg…
- Trial name
- NCT00774267
- Testing
- BZA 20 mg/CE 0.45 mg, BZA 20 mg/CE 0.625 mg, Raloxifene 60 mg
- Where
- 26 sites in United States, Brazil and 2 more
- Volunteers
- 507 people
- Sponsor
- Pfizer
Breast Cancer, Early Detection of Cancer
A Prospective Study to Evaluate Clinical Performance of Thermalytix in Detecting Breast Cancers
The purpose of this study is to determine the clinical performance of AI-based Thermalytix with the current standard-of-care diagnostic modalities in women.
- Trial name
- NCT04688086
- Testing
- Thermalytix
- Where
- India
- Volunteers
- 687 people, healthy volunteers welcome
- Sponsor
- Niramai Health Analytix Private Limited
Mammographic Breast Density
Topical Endoxifen in Women
Karma CREME-1 consisted of 90 participants from the Karma Cohort. The major focus of the pilot trial was to estimate time to mammographic density change.
- Trial name
- CREME (NCT04616430)
- Testing
- Topical endoxifen
- Where
- Sweden
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Atossa Therapeutics, Inc.
Hereditary Breast and Ovarian Cancer Syndrome, Osteoporosis
Zoledronate or Observation in Maintaining Bone Mineral Density in Patients Who Are Undergoing Surgery to Remove Both Ovaries
This randomized phase II trial is studying zoledronate to see how well it works compared to observation in maintaining bone mineral density in patients who are undergoing surgery to remove both ovaries.
- Conditions
- Hereditary Breast and Ovarian Cancer Syndrome, Osteoporosis, Ovarian Carcinoma
- Trial name
- NCT00305695
- Testing
- Laboratory Biomarker Analysis, Zoledronic Acid
- Where
- 95 sites in United States
- Volunteers
- 160 people
- Sponsor
- Gynecologic Oncology Group
Breast Cancer, Low Bone Mineral Density
AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer
The purpose of this trial is to evaluate AMG 162 in the treatment of bone loss in subjects undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer.
- Conditions
- Breast Cancer, Low Bone Mineral Density, Osteopenia
- Trial name
- NCT00089661
- Testing
- AMG 162 / Denosumab
- Volunteers
- 252 people
- Sponsor
- Amgen
Primary Hormone Receptor Negative Breast Cancer in Premenopausal Women
A Study of Zoledronic Acid in the Prevention of Cancer Therapy-induced Bone Loss
Breast cancer and osteoporosis are two of the most frequent diseases in women. Estrogen may be associated with bone loss and the risk of breast cancer because of its potent effects on the mitotic activity of breast epithelium and…
- Trial name
- NCT00333229
- Testing
- Zoledronic Acid
- Where
- Germany
- Volunteers
- 11 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
Vitamin D in Postmenopausal Women at High Risk for Breast Cancer
This is a phase II study which will enroll 20 postmenopausal women who are at high risk for breast cancer development. The goal is to determine whether a one-year intervention of high-dose vitamin D at 2 different doses (20,000…
- Trial name
- NCT00859651
- Testing
- Cholecalciferol
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Columbia University
Mammographic Breast Density
Trial of 4-Hydroxytamoxifen (4-OHT) Gel in Women Aimed at Reducing Dense Breast Tissue
A study to determine the efficacy of 8 mg/day (4 mg/breast) of BHR-700 gel compared to placebo for reducing breast tissue density in women identified as having dense breast tissue upon analysis of screening mammography.
- Trial name
- 4WARD (NCT03199963)
- Testing
- 4-OH tamoxifen
- Where
- 19 sites in United States, Germany and 1 more
- Volunteers
- 223 people
- Sponsor
- BHR Pharma, LLC
Breast Cancer
The Safety and Efficacy of Zoledronic Acid in the Prevention of Cancer Therapy Induced Bone Loss
This study examines the safety and efficacy of zoledronic acid 4 mg., given every 3 months over 24 months (infusion at month 0, 3, 6, 9, 12, 15, 18 and 21) in improving bone mineral density in premenopausal women with hormone…
- Trial name
- NCT00375505
- Testing
- Zoledronic acid
- Where
- Germany
- Volunteers
- 70 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
Nutritional Supplements and Hormonal Manipulations for Breast Cancer Prevention
The overall hypothesis is that the combination of a low dose of the antiestrogen Raloxifene with omega-3 fatty acids will exert a synergistic breast cancer chemopreventive effect due to the crosstalk of their downstream cellular…
- Trial name
- NCT00723398
- Testing
- Lovaza 4gm oral, Raloxifene 60 Mg Oral Tablet, Raloxifene 30 Mg Oral Tablet
- Where
- United States
- Volunteers
- 266 people, healthy volunteers welcome
- Sponsor
- Milton S. Hershey Medical Center
Breast Cancer
Soy Protein and Breast Cancer Risk Reduction
Soy consumption has been associated with reduced risk for developing breast cancer. Ovarian hormones and breast density are considered breast cancer risk markers.
- Trial name
- NCT00204477
- Testing
- soy milk, cow's milk
- Where
- United States
- Volunteers
- 321 people, healthy volunteers welcome
- Sponsor
- The University of Texas Medical Branch, Galveston
Inflammation, Cancer
NSAID Effects on Clinical and Imaging Breast Biomarkers
This study has two purposes. One is to determine if daily sulindac decreases breast density; a risk factor for breast cancer development.
- Conditions
- Inflammation, Cancer, Pain, Hypertension
- Trial name
- NCT01761877
- Testing
- Sulindac
- Where
- 2 sites in United States
- Volunteers
- 114 people
- Sponsor
- Stony Brook University
Breast Carcinoma
Molecular Breast Imaging and Digital Breast Tomosynthesis in Screening Patients With Dense Breast Tissue
This study compares molecular breast imaging (MBI) and digital breast tomosynthesis (DBT) in screening patients with dense breast tissue. Breast imaging may help doctors find breast cancer sooner, when it may be easier to treat.
- Trial name
- NCT03220893
- Testing
- Digital Breast Tomosynthesis (DBT), Scintimammography
- Where
- 5 sites in United States
- Volunteers
- 3,023 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic